Table 3.

Toxicity and efficacy data of patients treated with Bevacizumab according to creatinine clearance

CHARACTERISTICS	BEVACIZUMAB
	CrCl ≤ 60 ml/min N=5	CrCl > 60 ml/min N=8
Skin Rash (mild – moderate)	1(20%)	1 (12%)
Diarrhea (Grade 1- 2)	0	1 (13%)
Infections	1 (20%)	5 (63%)
Fatigue Mild Moderate Severe	0 2 (40%) 1 (20%)	4 (50%) 3 (38%) 1 (13%)
Proteinuria	2 (40%)	4 (50%)
Bleeding	1(20%)	2(25%)
Gastrointestinal perforations	0	0
Arterial or Venous Thrombotic events	0	1(12%)
Median Systolic BP prior to starting therapy (mm Hg) Median Diastolic BP prior to starting therapy (mm Hg)	131 (103–143) 64 (50-80)	144 (106-183) 83 (60-90)
Median rise in Systolic BP during therapy Median rise in Diastolic BP during therapy	42mm 18mm	21mm 12mm
Dose interruption(s)	3 (60%)	5 (63%)
Dose reduction(s)	1 (20%)	3 (37%)

^*Denominator indicates the number of patients tested if less than the total number